Agenus Inc (AGEN)
10.86
+0.36
(+3.43%)
USD |
NASDAQ |
May 17, 16:00
10.86
0.00 (0.00%)
After-Hours: 20:00
Agenus Accounts Receivable (Quarterly): 0.476M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.476M |
December 31, 2023 | 25.84M |
September 30, 2023 | 1.03M |
June 30, 2023 | 1.341M |
March 31, 2023 | 1.417M |
December 31, 2022 | 2.741M |
September 30, 2022 | 8.823M |
June 30, 2022 | 18.99M |
March 31, 2022 | 1.286M |
December 31, 2021 | 1.518M |
September 30, 2021 | 21.77M |
June 30, 2021 | 1.436M |
March 31, 2021 | 2.173M |
December 31, 2020 | 1.157M |
September 30, 2020 | 1.414M |
June 30, 2020 | 16.63M |
March 31, 2020 | 2.643M |
December 31, 2019 | 16.29M |
September 30, 2019 | 2.328M |
June 30, 2019 | 2.205M |
March 31, 2019 | 0.796M |
December 31, 2018 | 0.938M |
September 30, 2018 | 6.069M |
June 30, 2018 | 10.92M |
March 31, 2018 | 1.129M |
Date | Value |
---|---|
December 31, 2017 | 1.134M |
September 30, 2017 | 2.191M |
June 30, 2017 | 3.944M |
March 31, 2017 | 6.775M |
December 31, 2016 | 11.35M |
September 30, 2016 | 10.28M |
June 30, 2016 | 9.417M |
March 31, 2016 | 10.22M |
December 31, 2015 | 9.800M |
September 30, 2015 | 7.332M |
June 30, 2015 | 4.112M |
March 31, 2015 | 2.534M |
December 31, 2014 | 0.463M |
September 30, 2014 | 0.00 |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
December 31, 2013 | 0.0012M |
September 30, 2013 | 0.0011M |
June 30, 2013 | 0.2025M |
March 31, 2013 | 0.1637M |
December 31, 2012 | 0.5523M |
September 30, 2012 | 0.3691M |
June 30, 2012 | 0.0923M |
March 31, 2012 | 0.0587M |
December 31, 2011 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
0.476M
Minimum
Mar 2024
25.84M
Maximum
Dec 2023
6.576M
Average
2.189M
Median
Accounts Receivable (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 28.44M |
Protalix BioTherapeutics Inc | 3.759M |
InfuSystems Holdings Inc | 20.54M |
PAVmed Inc | 0.067M |
Allogene Therapeutics Inc | -- |